{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:38:51Z","timestamp":1786358331564,"version":"build-2736575974"},"reference-count":89,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Antibody\u2013drug conjugates (ADCs) have transformed the therapeutic landscape of breast cancer, expanding treatment opportunities across multiple disease settings. However, their increasing clinical use has revealed a heterogeneous spectrum of toxicities that extends beyond conventional chemotherapy-related adverse events. Emerging evidence suggests that ADC-associated toxicities are driven by a complex interplay between ADC structural characteristics, including target antigen expression, payload properties, linker stability, drug-to-antibody ratio, and patient-related susceptibility factors. This review aims to provide a comprehensive overview of ADC-related toxicities in breast cancer, integrating mechanistic insights with clinical management strategies and risk-adapted approaches. Methods: A narrative review of the literature was conducted focusing on clinical trials, real-world studies, translational investigations, and mechanistic evidence related to ADC-associated toxicities in breast cancer. Particular attention was given to the relationship between ADC design, toxicity mechanisms, patient-specific risk factors, and clinical management. Results: ADC-related toxicities encompass a broad range of adverse events, including hematologic toxicity, interstitial lung disease, gastrointestinal complications, hepatotoxicity, peripheral neuropathy, stomatitis, ocular toxicity, dermatologic adverse events, and cardiovascular manifestations. Current evidence indicates that toxicity profiles differ substantially across ADCs and are influenced by multiple factors, including payload class, linker chemistry, target biology, intracellular trafficking, bystander effects, systemic payload exposure, and host-related characteristics. While several toxicities can be anticipated through careful monitoring and early intervention, clinically significant variability remains, and validated predictive biomarkers are largely lacking. Emerging real-world evidence further highlights the importance of individualized toxicity assessment and multidisciplinary management. Conclusions: ADC-related toxicity should be viewed as a multifactorial biological process resulting from the interaction between ADC design and host susceptibility rather than as a uniform class effect. A mechanistic understanding of toxicity pathways may improve risk stratification, toxicity monitoring, and personalized management strategies. Future research should focus on the development of predictive biomarkers, pharmacologic risk models, and next-generation ADC platforms with improved therapeutic indices. This review proposes an integrated framework linking ADC structural determinants, toxicity mechanisms, and clinical management to support safer and more individualized use of ADCs in breast cancer.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070792","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:26:15Z","timestamp":1782807975000},"page":"792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicities of Antibody\u2013Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1414-529X","authenticated-orcid":false,"given":"Luisana","family":"Sisca","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"},{"name":"Department of Translational Research, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1586-8676","authenticated-orcid":false,"given":"Mariam","family":"Polito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"},{"name":"UOC Oncologia Territoriale-ASL Latina-CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Travisani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6649-5665","authenticated-orcid":false,"given":"Fernando","family":"Zannino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Iuliani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pantano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ballest\u00edn, P., L\u00f3pez de S\u00e1, A., D\u00edaz-Tejeiro, C., Paniagua-Herranz, L., Sanvicente, A., L\u00f3pez-Cade, I., P\u00e9rez-Segura, P., Alonso-Moreno, C., Nieto-Jim\u00e9nez, C., and Oca\u00f1a, A. (2025). Understanding the Toxicity Profile of Approved ADCs. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17020258"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Nguyen, T.D., Bordeau, B.M., and Balthasar, J.P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15.","DOI":"10.3390\/cancers15030713"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody\u2013drug conjugates in cancer therapy: Current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115648","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Theocharopoulos, C., Lialios, P.-P., Samarkos, M., Gogas, H., and Ziogas, D.C. (2021). Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Vaccines, 9.","DOI":"10.3390\/vaccines9101111"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tang, Z., Xie, Y., and Zeng, Y. (2025). Antibody\u2013drug conjugate: A newly developed biological missile for tumor treatment. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1688057"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, D., Yang, K., He, R., Yin, R., and Shui, L. (2025). Antibody-drug conjugates in cancer therapy: Current advances and prospects for breakthroughs. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1669592"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody\u2013drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"de Almeida, V.M., Soares, M.B.P., and Santos-Filho, O.A. (2025). Exploring Experimental and In Silico Approaches for Antibody\u2013Drug Conjugates in Oncology Therapies. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081198"},{"key":"ref_12","first-page":"157","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e71415","DOI":"10.1002\/cam4.71415","article-title":"HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer","volume":"14","author":"Lee","year":"2025","journal-title":"Cancer Med."},{"key":"ref_14","first-page":"e98924","article-title":"Comparative Efficacy and Safety of Antibody\u2013Drug Conjugates Versus Standard Chemotherapy in Metastatic Breast Cancer: A Comprehensive Systematic Review and Meta-Analysis","volume":"17","author":"Teama","year":"2025","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Esapa, B., Jiang, J., Cheung, A., Chenoweth, A., Thurston, D.E., and Karagiannis, S.N. (2023). Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers, 15.","DOI":"10.3390\/cancers15061845"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, X., Liu, J., Meng, Y., Li, J., Zhao, J., Liu, D., and Zhang, X. (2026). Frontiers in Antibody\u2013Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy. Pharmaceuticals, 19.","DOI":"10.3390\/ph19020324"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rao, M., Wu, L., Chen, H., Wu, X., Wang, H., Chen, Y., and Chen, C. (2025). Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0334513"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","volume":"393","author":"Punie","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO-25-02938","article-title":"WBC Growth Factors: ASCO Guideline Update","volume":"44","author":"Gyawali","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14740338.2025.2449991","article-title":"Hematological toxicities in antibody-drug conjugates related with breast cancer: A pharmacovigilance study using FDA adverse event reporting system database","volume":"25","author":"Wang","year":"2026","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10549-026-07971-z","article-title":"Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: A single-center retrospective analysis","volume":"217","author":"Tam","year":"2026","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Falc\u00f3n-Gonz\u00e1lez, A., Llabr\u00e9s-Valenti, E., Henao-Carrasco, F., Urbano-Cubero, R., Godoy-Ortiz, A., Nieto-Ram\u00edrez, J.C., Vargas-Prado, A.M., Gonz\u00e1lez-Haba, A., Mart\u00edn-Calero, B., and Morales-Est\u00e9vez, C. (2026). Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: Results from the multicenter retrospective observational SACISUR cohort in Southern Spain. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1717135"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1535-7163.MCT-24-0267","article-title":"Potential Mechanisms of Interstitial Lung Disease Induced by Antibody\u2013Drug Conjugates Based on Quantitative Analysis of Drug Distribution","volume":"24","author":"Koganemaru","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s12672-024-01705-7","article-title":"Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17588359251338624","DOI":"10.1177\/17588359251338624","article-title":"The impact of pre-existing interstitial lung disease on radiation and checkpoint inhibitor pneumonitis in lung cancer patients: A systematic review and meta-analysis","volume":"17","author":"Jiang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105847","DOI":"10.1016\/j.esmoop.2025.105847","article-title":"Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer","volume":"10","author":"Antonarelli","year":"2025","journal-title":"ESMO Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105511","DOI":"10.1016\/j.esmoop.2025.105511","article-title":"Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: A real-world, observational cohort study","volume":"10","author":"Nozawa","year":"2025","journal-title":"ESMO Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12282-025-01814-3","article-title":"Real-world analysis of interstitial lung disease\/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan","volume":"33","author":"Tsurutani","year":"2026","journal-title":"Breast Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41523-026-00936-x","article-title":"Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials","volume":"12","author":"Udovica","year":"2026","journal-title":"npj Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hourani, M., Bdair, R., Dawoud, E., Trad, D.A., Giridharan, S., Qawasmeh, K.A., Marashi, H., and Ansari, J. (2025). Assessment of the Efficacy and Pulmonary Toxicity of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer in a Tertiary Center in the United Arab Emirates. Cureus, 17.","DOI":"10.7759\/cureus.78471"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study","volume":"29","author":"Botticelli","year":"2024","journal-title":"Oncologist"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100095","DOI":"10.1016\/j.esmorw.2024.100095","article-title":"Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: A Hellenic Cooperative Oncology Group study","volume":"7","author":"Fountzilas","year":"2025","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.2026.44.16_suppl.1057","article-title":"Real-world cardiotoxicity with HER2 antibody\u2013drug conjugates and survival after treatment continuation","volume":"44","author":"Aziz","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_40","unstructured":"(2026, May 03). Posters-ESMO Breast Cancer 2026-Onsite and Online Congress. Available online: https:\/\/cslide.ctimeetingtech.com\/coasis_21571\/attendee\/confcal_1\/presentation\/list?q=gullotta."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shi, Y., Yao, K., Zhao, J., Yue, Y., and Wu, H. (2025). Gastrointestinal toxicity of antibody\u2013drug conjugates: A pharmacovigilance study using the FAERS database. BMC Pharmacol. Toxicol., 26.","DOI":"10.1186\/s40360-025-00877-4"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103853","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2025","journal-title":"Breast"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clbc.2024.04.003","article-title":"Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis","volume":"24","author":"Pedersini","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-P\u00e9rez, M., Nieto-S\u00e1nchez, M.T., D\u00edaz-Villamar\u00edn, X., Torres-Garc\u00eda, A., Fern\u00e1ndez-Var\u00f3n, E., Prados-Carmona, A., Leger\u00e9n, M., Cabeza-Barrera, J., Blancas, I., and Mor\u00f3n, R. (2026). The Early Safety Signal of Sacituzumab Govitecan-Related Toxicity and the UGT1A1*28 Genotype in Metastatic Breast Cancer: A Real-World Preliminary Report. J. Clin. Med., 15.","DOI":"10.3390\/jcm15051715"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.18632\/oncoscience.643","article-title":"Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection","volume":"13","author":"Hashim","year":"2026","journal-title":"Oncoscience"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bianchini, G., Arpino, G., Biganzoli, L., Lonardi, S., Puglisi, F., Santini, D., Lambertini, M., and Pappagallo, G. (2022). Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers, 14.","DOI":"10.3390\/cancers14041022"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/toxres\/tfab026","article-title":"Epidermal growth factor receptor inhibitor-induced diarrhea: Clinical incidence, toxicological mechanism, and management","volume":"10","author":"Tao","year":"2021","journal-title":"Toxicol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sharma, A., Kumar, H., Paladiya, R., Sisodia, R., Bharadwaj, H.R., Mohamed, I., Alsakarneh, S., Hayat, U., Sonaiya, S., and Pinnam, H.S. (2026). Antibody\u2013Drug Conjugates in Gastrointestinal Oncology: Clinical Efficacy and Inpatient Toxicity Management. J. Pers. Med., 16, Available online: https:\/\/www.mdpi.com\/2075-4426\/16\/4\/195.","DOI":"10.3390\/jpm16040195"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1093\/oncolo\/oyae177","article-title":"Ocular adverse events associated with antibody-drug conjugates for cancer: Evidence and management strategies","volume":"29","author":"Dy","year":"2024","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhou, J., Wang, H., Xie, H., Xu, X., and Xiao, H. (2026). Ocular toxicity associated with antibody-drug conjugates in cancer therapy: A comprehensive review. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1698458"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular Adverse Events Associated with Antibody\u2013Drug Conjugates in Human Clinical Trials-PMC","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mao, K., Chen, P., Sun, H., Zhong, S., Zheng, H., and Xu, L. (2024). Ocular adverse events associated with antibody-drug conjugates in oncology: A pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1425617"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101302","DOI":"10.1016\/j.preteyeres.2024.101302","article-title":"Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies","volume":"103","author":"Gabison","year":"2024","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cheng, X., Ji, S., Lee, Y., and Dong, H. (2026). Applications of Pharmacometrics in Antibody\u2013Drug Conjugate Development. Pharmaceutics, 18, Available online: https:\/\/www.mdpi.com\/1999-4923\/18\/3\/354.","DOI":"10.3390\/pharmaceutics18030354"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.gore.2023.101155","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e473384","DOI":"10.1200\/EDBK-25-473384","article-title":"New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies","volume":"45","author":"LeVee","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_58","first-page":"oyaf031","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Bardia","year":"2025","journal-title":"Oncologist"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12951-026-04117-7","article-title":"Targeted repair of oral mucosal injury: Emerging applications of biomaterials-based drug delivery systems","volume":"24","author":"Yu","year":"2026","journal-title":"J. Nanobiotechnology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1080\/14796694.2024.2407756","article-title":"Cardiac toxicity of HER-2 targeting antibody-drug conjugates: Overview and clinical implications","volume":"20","author":"Zalaquett","year":"2024","journal-title":"Future Oncol."},{"key":"ref_61","first-page":"e83012","article-title":"Cardiotoxic Effects of HER2-Targeted Therapies: Insights from a Retrospective Study at a Romanian Oncology Center","volume":"17","author":"Kajanto","year":"2025","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ciappina, G., Colarusso, L., Maiorana, E., Ottaiano, A., Franchina, T., Picone, A., Facchini, G., Barraco, C., Ieni, A., and Cusm\u00e0 Piccione, M. (2025). Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice. Pharmaceuticals, 18.","DOI":"10.3390\/ph18091399"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Long, P., Li, S., Pan, L., Wang, Y., Chen, W., and Wang, X. (2024). Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): A pharmacovigilance study based on the FAERS database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1378010"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Liu","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"B25","DOI":"10.1093\/eurheartjsupp\/suad062","article-title":"Cardiac toxicity of chemotherapy for breast cancer: Do angiotensin-converting enzyme inhibitors and beta blockers protect?","volume":"25","author":"Bisceglia","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2042098620915058","DOI":"10.1177\/2042098620915058","article-title":"Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: A systematic review and meta-analysis","volume":"11","author":"Cobert","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","article-title":"Pharmacovigilance study of the association between peripheral neuropathy and antibody\u2013drug conjugates using the FDA adverse event reporting system","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"102922","DOI":"10.1016\/j.esmoop.2024.102922","article-title":"Management of infusion-related reactions in cancer therapy: Strategies and challenges","volume":"9","author":"Barroso","year":"2024","journal-title":"ESMO Open"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104292","DOI":"10.1016\/j.critrevonc.2024.104292","article-title":"Incidence of antibody-drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis","volume":"196","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic toxicities of antibody-drug conjugates","volume":"91","author":"Gronbeck","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Su, D., and Zhang, D. (2021). Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.687926"},{"key":"ref_73","first-page":"575936","article-title":"Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review","volume":"18","author":"Wu","year":"2026","journal-title":"Breast Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"17588359251324889","DOI":"10.1177\/17588359251324889","article-title":"Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer","volume":"17","author":"Kang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.chest.2021.06.035","article-title":"Detection and Early Referral of Patients with Interstitial Lung Abnormalities","volume":"161","author":"Hunninghake","year":"2022","journal-title":"Chest"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaccao.2024.12.007","article-title":"Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance","volume":"7","author":"Ali","year":"2025","journal-title":"JACC CardioOncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40261-024-01400-z","article-title":"Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: A Multidisciplinary Viewpoint by Portuguese Experts","volume":"44","author":"Campainha","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"103309","DOI":"10.1016\/j.eclinm.2025.103309","article-title":"Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial","volume":"85","author":"Gion","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_80","first-page":"756","article-title":"US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan","volume":"33","author":"Rugo","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Dong, Y., Zhi, Y., Li, X., Ma, M., Ye, M., Huang, S., Tang, J., Zhong, W., Lei, X., and Mao, Y. (2025). Navigating hepatotoxicity of antibody-drug conjugates: From mechanistic insights to clinical and postmarketing evidence. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1694436"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100595","DOI":"10.1016\/j.apjon.2024.100595","article-title":"Management of neurotoxic reactions induced by antibody-drug conjugates","volume":"11","author":"Zhang","year":"2024","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hulme, K., Safari, R., Thomas, S., Mercer, T., White, C., Van der Linden, M., and Moss-Morris, R. (2018). Fatigue interventions in long term, physical health conditions: A scoping review of systematic reviews. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203367"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: Recommendations of an expert panel","volume":"95","author":"Eris","year":"2020","journal-title":"Bras. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e7403","DOI":"10.1002\/cam4.7403","article-title":"Multidisciplinary management of immunotherapy-related adverse events in solid tumors: An inter-institutional and telemedicine-based working team","volume":"13","author":"Iaculli","year":"2024","journal-title":"Cancer Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Maniaci, A., Lavalle, S., Gagliano, C., Lentini, M., Masiello, E., Parisi, F., Iannella, G., Cilia, N.D., Salerno, V., and Cusumano, G. (2024). The Integration of Radiomics and Artificial Intelligence in Modern Medicine. Life, 14.","DOI":"10.3390\/life14101248"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wu, G., Yuan, Z., Chen, M., Tang, X., Wang, F., and Zhang, D. (2026). Antibody\u2013Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives. Molecules, 31.","DOI":"10.3390\/molecules31071180"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:27:01Z","timestamp":1786357621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":89,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070792"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070792","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}